Corvus Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
I'm not the analyst for Jefferies, I'm Richard Miller, I'm the CEO of Corvus. Really appreciate you all coming out to listen to this presentation. I have a lot to cover, so I think I'm going to jump right in. So let me have the next slide, I guess my control this.
What I'd like to do today is talk to you about three products that we have in the clinic, an ITK inhibitor, small molecule, A2A receptor antagonist, and an anti-CD73 antibody. I'm going to spend majority of the time, the bulk of the time talking about a drug we're pretty excited about. It's called an ITK inhibitor, I'll tell you all about that in a little bit.
This drug again, is a small molecule. Orally administered, is now, in a Phase-1b trial for relapsed T-cell lymphomas. We'll be reporting updated data on that in a couple of weeks at the Lugano meeting in Switzerland, International Conference on Malignant Lymphoma.
We plan to have additional data throughout the rest of the year. We are planning to meet with the FDA in late summer to discuss a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
